[1] Zheng, Q.C. Analysis of 76 cases of chronic pulmonary heart disease [J]. Chinese Journal of Coal Industry Medicine, 2010,13(12), 1786–1787.
[2] Mei, X.M., & Zhang, X.R. Progress in diagnosis and treatment of chronic pulmonary heart disease [J]. Gems of Health, 2012,11(7), 532–532.
[3] Li, N., Zhao Z.H., & Wan, C.H. Research on the influencing factors for living quality of patients with chronic pulmonary heart disease [J] Journal of Qiqihar Medical University, 2010,31(4), 513–514.
[4] Li, N., Zhao, Z.H., & Wan, C.H. Relationships between quality of life and clinical indicators of patients with chronic pulmonary heart disease [J] Journal of Jilin University (Medicine Edition),2012, 38(3), 580–585.
[5] Wang, G.H., Li, X.M., Wan, C.H., et al. . Development and evaluation of quality of life instrument for patients with chronic pulmonary heart disease [J]. Chinese Journal of Public Health, 2009,25(10), 1224–1226.
[6] Ramírez-Vélez, R. Quality of life and social support for patients suffering from chronic obstructive pulmonary disease [J]. Rev Salud Publica (Bogota), 2007,9(4), 568–575.
[7] Shafazand S, Goldstein MK, Doyle RL, et al. Health-related quality of life in patients with pulmonary arterial hypertension [ J ]. Chest, 2004, 126(5), 1452–1459.
[8] Karapolat H, Eyigor S, Atasever A, et al. Effect of dyspnea and clinical variables on the quality of life and functional capacity in patients with chronic obstructive pulmonary disease and congestive heart failure [J]. Chinese Medical Journal (English), 2008, 121(7), 592–596.
[9] Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension[J]. Circulation, 2006, 114(14), 1482–1489.
[10] Ulrich S, Speich R, Domenighetti G, et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study) [J]. Swiss Medical Weekly, 2007,137(41–42), 573–580.
[11] Wan C, Tu X, Messing S, et al. Development and validation of the general module of the system of quality of life instruments for chronic diseases and its comparison with SF-36[J]. Journal of Pain & Symptom Management, 2011, 42(1), 93–104.
[12] Wan CH. Measurement and assessment of quality of life [M]. Kunming: Yunnan University Press, 1999, 1–90.
[13] Yang Z, Qi YB, Wan CH, et al. Using item response theory to analyze general module of quality of life instruments for chronic diseases [J]. Chinese General Practice, 2012, 15 (22), 2544–2547.
[14] Yanchun S, Zheng Y, Chonghua W, et al. Development and validation of the pulmonary tuberculosis scale of the system of Quality of Life Instruments for Chronic Diseases (QLICD-PT). Health and Quality of Life Outcomes, 2018, 16(1), 137–[last page number].
[15] Samsa G, Matchar DB, Dolor RJ, et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation[J]. Health Qual Life Outcomes, 2004, 2(1), 22.
[16] Wan CH, Zhao XD, Li XM, et al. Comparison of two instruments on measuring quality of life for patients with chronic diseases [J]. Chinese Journal of Public Health, 2007, 23(7), 815–817.
[17] Wu J, Hu L, Zhang G, et al. Development and validation of the nasopharyngeal cancer scale among the system of quality of life instruments for cancer patients (QLICP-NA V2.0): combined classical test theory and generalizability theory[J]. Quality of Life Research, 2016, 25(8), 2087–2100.
[18] Xiaohui R, Chaojie L, Ningxiu L. Assessing the Quality of Life of People with Chronic Diseases Using SF-36[J]. Journal of West China University of Medical Sciences, 2001, 32(2), 250–253.
[19] Guan YX, Jin SD, Lu N, et al. Hope level and social support status of patients with chronic pulmonary heart disease and their correlation [J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2015 (1), 92–94.